title: Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
abstract: OBJECTIVE
  Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [(18)F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer.
  
  
  METHODS
  Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM.
  
  
  RESULTS
  No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [(18)F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi).
  
  
  CONCLUSIONS
  [(18)F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [(18)F]DCFPyL is similar to that from other PET radiotracers.
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Cancer Research Bldg. 2, Room 492, 1550 Orleans St, Baltimore, MD, 21231, USA.
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Szabo
authors.forename: Esther
authors.initials: E
authors.lastname: Mena
authors.forename: Steven P
authors.initials: SP
authors.lastname: Rowe
authors.forename: Donika
authors.initials: D
authors.lastname: Plyku
authors.forename: Rosa
authors.initials: R
authors.lastname: Nidal
authors.forename: Mario A
authors.initials: MA
authors.lastname: Eisenberger
authors.forename: Emmanuel S
authors.initials: ES
authors.lastname: Antonarakis
authors.forename: Hong
authors.initials: H
authors.lastname: Fan
authors.forename: Robert F
authors.initials: RF
authors.lastname: Dannals
authors.forename: Ying
authors.initials: Y
authors.lastname: Chen
authors.forename: Ronnie C
authors.initials: RC
authors.lastname: Mease
authors.forename: Melin
authors.initials: M
authors.lastname: Vranesic
authors.forename: Akrita
authors.initials: A
authors.lastname: Bhatnagar
authors.forename: George
authors.initials: G
authors.lastname: Sgouros
authors.forename: Steve Y
authors.initials: SY
authors.lastname: Cho
authors.forename: Martin G
authors.initials: MG
authors.lastname: Pomper
mesh_terms: D000368:Aged; D000954:Antigens, Surface / Q000378:metabolism*; D005240:Feasibility Studies; D043425:Glutamate Carboxypeptidase II / Q000378:metabolism*; D006801:Humans; D008239:Lysine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D011874:Radiometry; D014018:Tissue Distribution; D014508:Urea / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: C572626:2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid; D000954:Antigens, Surface; D014508:Urea; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D008239:Lysine